DPHARM: How to address the clinical trial enrollment crisis?

The clinical trial enrollment crisis is causing significant delays and financial losses in the biopharma industry, with 80% of trials not meeting enrollment timelines and less than 5% of eligible cancer patients participating. Industry leaders suggest expanding community medicine trial sites, leveraging AI in electronic health records, and improving patient engagement to accelerate enrollment and ensure representative trial participation in the U.S.

This Wire brief sits within Fusion42's coverage of Biotech.